CM
AVBP icon

Caption Management’s ArriVent BioPharma AVBP Stock Holding History

Caption Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Hold
15,967
– – ﹤0.01% 1298
2026
Q1 		$368K Buy
+15,967
New +$361K ﹤0.01% 1264
2025
Q4 		– Sell
-7,000
Closed -$129K – 2146
2025
Q3 		$129K Buy
+7,000
New +$138K ﹤0.01% 1517

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caption Management's AVBP Position: Q2 2026 in Review

Caption Management held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 15,967 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #1298.

Caption Management first reported a position in AVBP in Q3 2025 and has held it in 3 quarters since. 141 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Caption Management held 15,967 shares of ArriVent BioPharma worth $555K as of Q2 2026.
  • Caption Management left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1298 holding.
  • Caption Management first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 3 quarters since.
  • 141 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.